In a report released today, Charles Pitman CFA from Barclays maintained a Buy rating on UCB SA (0NZT – Research Report), with a price target of €175.00. The company’s shares closed last ...

Barclays analyst Charles Pitman CFA maintained a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €175.00. The company’s shares closed last Friday at €183.75.

The week after seeing its partner Roche cut and run, UCB has reported the failure of its anti-tau antibody bepranemab to improve cognition and function in people with early Alzheimer’s disease.

In September 2024, UCB and Biogen reported successful results from their Phase III clinical trial of the PHOENYCS GO study, which tested dapirolizumab pegol as a treatment for moderate-to-severe ...

The PEGylated Proteins Market is primarily driven by the growing demand for effective drug delivery systems, particularly in the treatment of chronic diseases such as cancer, hepatitis, and rheumatoid ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The Universal College Bangladesh (UCB) recently hosted an orientation session for the newly launched University of Central Lancashire (UCLan) programme. With this, UCB now offers several full UK ...

Copyright © 2024 MarketWatch, Inc. All rights reserved.

South Africa is the home of golf on the African continent by a long shot, with the number of courses topping 450. While the Western Cape province possesses the most courses in this year’s ...

African governments should give fibre optic cables greater protection from attacks and harmonize policies around layouts to ...